Rossari Biotech Limited Q3 FY26 Concall Decoded:Revenue grew 13%, margins sulked, and management decided Saudi Arabia is the new Silvassa. Bold.
1. Opening Hook
Just when everyone thought specialty chemicals were done sulking after festive demand fizzles, Rossari walked in with a calm smile and a Saudi passport application. Domestic demand stayed soft, margins slipped, and yet the company chose this exact moment to announce a greenfield expansion in KSA. Because why worry about EBITDA today when geopolitics can be your growth story tomorrow?
Q3 FY26 wasn’t flashy—no fireworks, no margin miracles—but it wasn’t a disaster either. Revenue moved up, profits refused to collapse, and management kept repeating words like “long-term,” “phased,” and “disciplined” like a chemical mantra. Institutional and B2C bled less than before, core segments stayed upright, and exports quietly did the heavy lifting.
Stick around—because beneath the polite numbers and cautious tone, Rossari is laying a very expensive bet on future relevance. And those bets always come with fine print.
2. At a Glance
Revenue up 13.5% YoY – Growth showed up, just not wearing party clothes.
EBITDA up 6.3% YoY – Lagged revenue, proving costs still lift heavier than volumes.
PAT up 3.5% YoY – Profits moved, but only after checking the weather twice.
Finance costs up 57% – Debt quietly entered the chat.
Exports steady – When India snoozed, overseas customers kept the lights on.
3. Management’s Key Commentary
“We delivered healthy YoY growth despite a softer domestic demand environment.” (Translation: Demand was weak, but we’ll take 13% and call it healthy.) 😏
“Diversified performance across segments helped offset moderation.” (Some businesses slowed, others ran faster—team effort saved the quarter.)
“Profitability was impacted by investments in capacity expansion.” (Margins were sacrificed at the altar of future scale.)
“Operational losses in Institutional and B2C reduced sequentially.” (Still losing money, but now with better manners.)
“Exports continued to support overall performance.” (Global customers are currently more reliable than domestic ones.)
“Board has granted in-principle approval for KSA manufacturing facilities.” (We’re thinking global—execution risk postponed for later.) 🚀
“We remain confident operating leverage will support margin improvement.” (Trust us. Just not this quarter.)
4. Numbers Decoded
Metric
Q3 FY26
YoY Take
Revenue
₹581.7 cr
Growth intact, demand patchy
EBITDA
₹68.9 cr
Costs ran ahead of chemistry
EBITDA Margin
11.8%
Expansion tax clearly visible
PAT
₹32.8 cr
Barely grew, but didn’t crack
Finance Cost
₹7.7 cr
Leverage warming up
Export Mix
~27%
Silent stabiliser
Decoded: Core chemistry is working. The P&L is just
